Our Pricing

Wegovy In Stock UK: Buy Online with Next-Day Delivery

Published on: June 03, 2026

Looking to buy Wegovy online UK next day delivery? Cured Pharmacy stocks genuine UK-licensed Wegovy (semaglutide) injection pens from £79.00 with transparent pricing, free clinical consultation under 3 minutes, and discreet next-day delivery across the UK. All prescriptions are issued by our UK-registered clinical team following a comprehensive online assessment.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics a natural hormone that regulates appetite and food intake by acting on areas of the brain involved in hunger regulation.

In the landmark STEP 1 clinical trial, participants receiving once-weekly semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Approximately 86.4% of participants on semaglutide lost at least 5% of their initial body weight, whilst 69.1% achieved at least 10% weight loss [1].

The medication works by slowing gastric emptying, reducing appetite, and increasing feelings of fullness after meals. These combined mechanisms help patients adhere to reduced-calorie diets more comfortably, supporting sustained weight loss when combined with lifestyle modifications [2].

Wegovy Availability and Stock Status in the UK

Following global supply constraints in 2022-2023, Wegovy availability has significantly improved across UK pharmacies. At Cured Pharmacy, we maintain regular stock of all Wegovy dose strengths, from the 0.25mg starter dose through to the 2.4mg maintenance dose, ensuring continuity of treatment for our patients.

Our pharmacy team monitors stock levels daily and works directly with licensed UK wholesalers to guarantee consistent availability. When you complete your online consultation and receive prescriber approval, we dispatch your medication the same working day for next-day delivery, subject to order placement before our daily cut-off time.

Unlike some providers who may show products as available but then notify patients of delays, we only accept consultations when we have confirmed stock in our GPhC-registered pharmacy premises. This transparent approach means you can trust that your Wegovy prescription will be fulfilled promptly.

What to Expect During Supply

Your initial prescription typically covers the dose-escalation phase, starting with 0.25mg weekly injections for four weeks, then increasing gradually to minimise gastrointestinal side effects. Our clinical team provides a clear dosing schedule with your first order, and we offer automatic reminders when it's time to reorder your next dose strength.

Buy Wegovy Online UK: The Cured Pharmacy Process

Purchasing Wegovy through Cured Pharmacy follows a straightforward, fully regulated process designed to meet MHRA and GPhC standards whilst prioritising patient convenience. The entire journey from consultation to delivery typically takes 24-48 hours.

First, you complete our free online medical consultation, which takes under 3 minutes. Our questionnaire covers your medical history, current medications, weight loss goals, and any contraindications. This information is reviewed by one of our UK-registered prescribers—qualified doctors or independent prescribers—who assess your suitability for Wegovy based on NICE guidance and clinical best practice [3].

Once approved, your prescription is issued electronically and sent directly to our pharmacy team. We dispense your medication in 100% discreet packaging with no external branding, and dispatch via next-day courier with tracking. You'll receive email and SMS updates at every stage, and our pharmacist-led support team remains available throughout your treatment journey.

Transparent Pricing Before Consultation

At Cured Pharmacy, you see the exact price before starting your consultation—no hidden fees, no surprise charges. Our lowest prices guaranteed policy means you're getting competitive UK pricing with the added value of expert clinical oversight and ongoing support from our superintendent pharmacist Tarun Kumar (GPhC 2233073) and his team.

Wegovy Dosing Schedule and Administration

Wegovy is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The pre-filled FlexTouch pen is designed for self-administration and requires no mixing or preparation—simply attach a new needle, dial your dose, and inject.

The treatment follows a structured dose-escalation protocol over 16-20 weeks to reach the maintenance dose of 2.4mg weekly. This gradual increase helps your body adjust and significantly reduces the likelihood of gastrointestinal side effects such as nausea or vomiting [2]. The standard schedule begins at 0.25mg weekly for four weeks, then increases to 0.5mg, 1mg, 1.7mg, and finally 2.4mg, with each step lasting four weeks.

If you experience persistent side effects at any stage, your prescriber may recommend staying at your current dose for an additional four weeks before escalating. Clinical trials have shown that slower titration improves treatment adherence without compromising long-term weight loss outcomes [1].

Injection Technique and Storage

Store your Wegovy pens in the refrigerator between 2°C and 8°C until first use. Once in use, pens may be kept at room temperature (below 30°C) for up to 28 days. Rotate injection sites weekly to prevent lipodystrophy, and never inject into areas that are tender, bruised, or scarred. Detailed injection guides and video tutorials are provided with your first order.

Wegovy vs Other Weight Loss Treatments

Wegovy is one of several prescription weight loss medications available through Cured Pharmacy, each with distinct mechanisms, efficacy profiles, and suitability criteria. Understanding these differences helps you and your prescriber select the most appropriate treatment for your individual circumstances.

Compared to earlier GLP-1 treatments, Wegovy offers the advantage of once-weekly dosing and higher average weight loss in clinical trials. However, newer dual-pathway treatments like tirzepatide have demonstrated even greater efficacy in head-to-head studies, with average weight reductions exceeding 20% in some patient groups [4].

Oral medications such as orlistat work through a completely different mechanism—blocking fat absorption in the gut—and may be more suitable for patients who prefer not to use injections or have contraindications to GLP-1 therapies. Your UK prescriber will consider your medical history, previous weight loss attempts, comorbidities, and personal preferences when recommending the optimal treatment pathway.

Common Side Effects and Safety Considerations

The most frequently reported side effects of Wegovy are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal pain. In clinical trials, these effects were generally mild to moderate, occurred predominantly during dose escalation, and decreased over time [1][2].

Approximately 7% of participants in the STEP trials discontinued treatment due to gastrointestinal adverse events [1]. To minimise discomfort, eat smaller meals, avoid high-fat foods, and stay well-hydrated. If nausea persists, contact our clinical team—adjusting your dose escalation schedule often resolves symptoms without discontinuing treatment.

Serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans) [2]. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your prescriber will screen for these conditions during your consultation.

Regular monitoring is recommended throughout treatment. Our clinical team encourages patients to report any persistent abdominal pain, changes in vision, or signs of allergic reaction immediately. We provide ongoing support via phone, email, and follow-up consultations to ensure your treatment remains safe and effective.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Side effects can occur; read the patient information leaflet carefully and report any concerns to your prescriber or pharmacist.